ClinicalTrials.gg
CompletedNCT01627782Updated Apr 29, 2025Results posted

A Study of Ketamine in Patients With Treatment-resistant Depression

A Phase 2 interventional study of Placebo and Ketamine in Major Depressive Disorder, sponsored by Janssen Research & Development, LLC. Completed at 13 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 89 studies testing ketamine in Depressive Disorder, Major — 21 open to participants now, 26 under way, 5 of them phase 3. Ketamine · Depressive Disorder, Major.

Enrollment
26th of 89
68 · median 38
Started
2012
with 7 others
Phase 2
22 of 89
7 open now
Registered
12th of 89
by date
Lead sponsor
3 of 89
Janssen Research & Development, LLC

Among the 89 studies testing ketamine in Depressive Disorder, Major, this one is the 26th largest by enrollment, is one of 8 that started in 2012, is one of 22 in phase 2, and was the 12th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

21 of the 89 studies testing ketamine in Depressive Disorder, Major are open now, in 9 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About ketamine

Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies testing ketamine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to explore the optimal dose frequency of ketamine in patients with treatment-resistant depression (TRD).

Read the detailed description

This is a double-blind (patients and study personnel do not know the identity of the administered treatments), randomized (the drug is assigned by chance), placebo-controlled (placebo is a substance that appears identical to the treatment and has no active ingredients), parallel arm study (each group of patients will be treated at the same time). The study will consist of a screening phase of up to 4 weeks, a 4-week double-blind treatment phase (Day 1 to Day 29), and a 3-week post treatment (follow up) phase. In the double-blind phase, patients will receive over 4 weeks either intravenous (IV) infusions of placebo (2 or 3 times weekly) or IV infusions of ketamine (2 or 3 times weekly). The total study duration for each patient will be a maximum of 13 weeks.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Major depressive disorder
  • Treatment-resistant depression
  • Ketamine
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be medically stable on the basis of clinical laboratory tests performed at screening
  • Meet diagnostic criteria for recurrent major depressive disorder (MDD), without psychotic features
  • Have a history of inadequate response, ie treatment was not successful, to at least 1 antidepressant
  • Have an Inventory of Depressive Symptoms-Clinician rated, 30 item (IDS-C30) total score >= 40 at screening and predose at Day 1
  • Inpatient or agreed to be admitted to the clinic on each dosing day

Exclusion criteria

Exclusion Criteria:

  • Has uncontrolled hypertension
  • Has a history of, or current signs and symptoms of diseases, infections or conditions that in the opinion of the investigator, would make participation not be in the best interest (eg, compromise the well-being) of the patient or that could prevent, limit, or confound the protocol-specified assessments
  • Has known allergies, , or intolerance to ketamine or its
  • Is unable to read and understand the consent forms and patient reported outcomes, complete study-related procedures, and/or communicate with the study staff
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
68 participants (actual)

Study arms

  • Placebo comparator
    Placebo 3 times/week

    Drug: Placebo

  • Experimental
    Ketamine 3 times/week

    Drug: Ketamine

  • Experimental
    Ketamine 2 times/week

    Drug: Ketamine

  • Placebo comparator
    Placebo 2 times/week

    Drug: Placebo

Interventions

  • DrugPlacebo

    Form= intravenous infusion, route= intravenous (IV) use. IV infusions of placebo 2 times weekly or IV infusions of placebo 3 times weekly.

  • Type= exact number, unit= mg/kg, number= 0.5, form= intravenous infusion, route= intravenous (IV) use. IV infusions of ketamine 0.50 mg/kg, 2 times weekly or IV infusions of ketamine 0.50 mg/kg, 3 times weekly.

06

What researchers measure

Primary outcomes

  1. Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 15

    The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.

    Time frame: Baseline (Day 1) and Day 15

Secondary outcomes

  1. Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 29

    The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.

    Time frame: Baseline (Day 1) and Day 29

  2. Number of Responders Based on Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

    Participants with a reduction in the MADRS total score of greater than or equal to (\>=) 50 percent from baseline were defined as responders. The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.

    Time frame: Day 15 and Day 29

  3. Number of Remitters Based on Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

    Participants who had a MADRS total score of less than or equal to (\<=) 10 were considered remitters. The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.

    Time frame: Day 15 and Day 29

  4. Number of Sustained Responders Based on Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

    Sustained response on Day 15 was defined as achieving an onset of antidepressant response within the first week that is maintained to the end of study Day 15. The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.

    Time frame: Day 15

  5. Change in Clinical Global Impression-Severity (CGI-S) Score From Baseline to Endpoint (Day 29)

    The CGI-S was used to rate the severity of the participants illness at the time of assessment, relative to the clinician's past experience with participants who had the same diagnosis and improvement with treatment. Considering total clinical experience, a participant was assessed on severity of mental illness at the time of rating according to: 0= not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill participants.

    Time frame: Baseline (Day 1) and Endpoint (Day 29)

  6. Clinical Global Impression of Improvement (CGI-I) Score at Endpoint of Double Blind Phase

    The CGI-I is a 7-point scale that was used to assess how much the participants illness was improved or worsened relative to a baseline state at the beginning of the intervention and rated as: 0= not assessed; 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse.

    Time frame: Endpoint (Day 29)

  7. Change in Patient Global Impression-Severity (PGI-S) Score From Baseline to Endpoint (Day 29)

    The PGI-S is an 11-point (0 to 10) scale that required the participant to rate the severity of their illness at the time of assessment, relative to the participants past experience. Considering their total experience, the participant was to assess the severity of their depression illness at the time of rating as none, mild, moderate or severe. The scale is rated as, 0=very well and 10=very poor.

    Time frame: Baseline (Day 1) and Endpoint (Day 29)

  8. Patient Global Impression-Change (PGI-C) Score at Endpoint of Double Blind Phase

    The PGI-C is a 7-point scale that required the subject to assess how much their illness had improved or worsened relative to a baseline state at the beginning of the intervention. The response options were: very much improved; much improved; improved (just enough to make a difference); no change; worse (just enough to make a difference); much worse; or very much worse. The scale is rated as, 1=very much improved and 7=very much worse.

    Time frame: Endpoint (Day 29)

  9. Maximum Observed Plasma Concentration (Cmax) of Ketamine

    The Cmax is the maximum observed plasma concentration of drug.

    Time frame: Pre-infusion, 20, 40 (End of the Infusion), 45, 50, 60, 90, 120, 180, 240 and 360 minutes post-infusion on Day 1 and Day 15

  10. Time to Reach Maximum Observed Plasma Concentration (Tmax) of Ketamine

    The Tmax is defined as actual sampling time to reach maximum observed drug concentration.

    Time frame: Pre-infusion, 20, 40 (End of the Infusion), 45, 50, 60, 90, 120, 180, 240 and 360 minutes post-infusion on Day 1 and Day 15

  11. Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time (AUC[0-last])

    The AUC(0-last) is the area under the plasma concentration-time curve from time zero to last quantifiable time.

    Time frame: Pre-infusion, 20, 40 (End of the Infusion), 45, 50, 60, 90, 120, 180, 240 and 360 minutes post-infusion on Day 1 and Day 15

  12. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity])

    The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC (last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.

    Time frame: Pre-infusion, 20, 40 (End of the Infusion), 45, 50, 60, 90, 120, 180, 240 and 360 minutes post-infusion on Day 1 and Day 15

  13. Total Systemic Clearance (CL) of Ketamine

    The CL is a quantitative measure of the rate at which a drug substance is removed from the body.

    Time frame: Pre-infusion, 20, 40 (End of the Infusion), 45, 50, 60, 90, 120, 180, 240 and 360 minutes post-infusion on Day 1 and Day 15

  14. Volume of Distribution at Steady-State (Vss) of Ketamine

    The Vss is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of ketamine at steady state.

    Time frame: Pre-infusion, 20, 40 (End of the Infusion), 45, 50, 60, 90, 120, 180, 240 and 360 minutes post-infusion on Day 1 and Day 15

  15. Elimination Half-Life (t1/2)

    The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).

    Time frame: Pre-infusion, 20, 40 (End of the Infusion), 45, 50, 60, 90, 120, 180, 240 and 360 minutes post-infusion on Day 1 and Day 15

07

Results

Posted Aug 5, 2016

Participant flow

Participant flow — Overall Study
MilestonePlacebo: 2 Times Per WeekKetamine: 2 Times Per WeekPlacebo: 3 Times Per WeekKetamine: 3 Times Per Week
Started17181617
Treated16181617
Completed112111
Not completed166156
Withdrew: Adverse event1201
Withdrew: Lack of efficacy111152
Withdrew: Protocol violation1000
Withdrew: Withdrawal by subject2100
Withdrew: Other0203
Withdrew: Randomized but not treated1000

Outcome measures

PrimaryChange in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 15

The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.

Time frame:
Baseline (Day 1) and Day 15
Reported as:
Mean · Units on a scale
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 15
Units on a scalePlacebo: 2 Times Per WeekKetamine: 2 Times Per WeekPlacebo: 3 Times Per WeekKetamine: 3 Times Per Week
Baseline (n=16,18,16,17)35.6 ± 3.7933.3 ± 4.9136.8 ± 5.8335.4 ± 5.28
Change at Day 15 (n=13,16,16,13)-5.7 ± 10.23-18.4 ± 12.01-3.1 ± 5.67-17.7 ± 7.27
Statistical analysis
  • Placebo: 2 Times Per Week vs Ketamine: 2 Times Per Week · Mixed Effect Model Repeated Measure · p = < 0.001 · Difference of least square means: -16.0 · 70% CI -20.00 to -12.01
  • Placebo: 3 Times Per Week vs Ketamine: 3 Times Per Week · Mixed Effect Model Repeated Measure · p = < 0.001 · Difference of least square means: -16.4 · 70% CI -18.96 to -13.84
SecondaryChange in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 29

The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.

Time frame:
Baseline (Day 1) and Day 29
Reported as:
Mean · Units on a scale
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 29
Units on a scalePlacebo: 2 Times Per WeekKetamine: 2 Times Per WeekPlacebo: 3 Times Per WeekKetamine: 3 Times Per Week
Baseline (n=16,18,16,17)35.6 ± 3.7933.3 ± 4.9136.8 ± 5.8335.4 ± 5.28
Change at Day 29 (n=2,13,1,13)-23.5 ± 10.61-27.1 ± 6.60-1 ± NA-22.9 ± 10.61
SecondaryNumber of Responders Based on Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

Participants with a reduction in the MADRS total score of greater than or equal to (\>=) 50 percent from baseline were defined as responders. The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.

Time frame:
Day 15 and Day 29
Reported as:
Number · Participants
Number of Responders Based on Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
ParticipantsPlacebo: 2 Times Per WeekKetamine: 2 Times Per WeekPlacebo: 3 Times Per WeekKetamine: 3 Times Per Week
Day 15 (n=13,16,16,13)2 ± 3.7911 ± 4.911 ± 5.837 ± 5.28
Day 29 (n=2,13,1,13)1 ± 10.6113 ± 6.600 ± NA9 ± 10.61
SecondaryNumber of Remitters Based on Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

Participants who had a MADRS total score of less than or equal to (\<=) 10 were considered remitters. The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.

Time frame:
Day 15 and Day 29
Reported as:
Number · Participants
Number of Remitters Based on Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
ParticipantsPlacebo: 2 Times Per WeekKetamine: 2 Times Per WeekPlacebo: 3 Times Per WeekKetamine: 3 Times Per Week
Day 15 (n=13,16,16,13)1 ± 3.796 ± 4.910 ± 5.833 ± 5.28
Day 29 (n=2,13,1,13)1 ± 10.6112 ± 6.600 ± NA5 ± 10.61
SecondaryNumber of Sustained Responders Based on Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

Sustained response on Day 15 was defined as achieving an onset of antidepressant response within the first week that is maintained to the end of study Day 15. The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.

Time frame:
Day 15
Reported as:
Number · Participants
Number of Sustained Responders Based on Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
ParticipantsPlacebo: 2 Times Per WeekKetamine: 2 Times Per WeekPlacebo: 3 Times Per WeekKetamine: 3 Times Per Week
Number of Sustained Responders Based on Montgomery-Asberg Depression Rating Scale (MADRS) Total Score1 ± 3.797 ± 4.910 ± 5.834 ± 5.28
SecondaryChange in Clinical Global Impression-Severity (CGI-S) Score From Baseline to Endpoint (Day 29)

The CGI-S was used to rate the severity of the participants illness at the time of assessment, relative to the clinician's past experience with participants who had the same diagnosis and improvement with treatment. Considering total clinical experience, a participant was assessed on severity of mental illness at the time of rating according to: 0= not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill participants.

Time frame:
Baseline (Day 1) and Endpoint (Day 29)
Reported as:
Median · Units on a scale
Change in Clinical Global Impression-Severity (CGI-S) Score From Baseline to Endpoint (Day 29)
Units on a scalePlacebo: 2 Times Per WeekKetamine: 2 Times Per WeekPlacebo: 3 Times Per WeekKetamine: 3 Times Per Week
Baseline (n=15,18,16,17)5.0 ± 3.795.0 ± 4.915.0 ± 5.835.0 ± 5.28
Change at Endpoint (n=15,18,16,17)0.0 ± 10.61-2.0 ± 6.600.0 ± NA-2.0 ± 10.61
SecondaryClinical Global Impression of Improvement (CGI-I) Score at Endpoint of Double Blind Phase

The CGI-I is a 7-point scale that was used to assess how much the participants illness was improved or worsened relative to a baseline state at the beginning of the intervention and rated as: 0= not assessed; 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse.

Time frame:
Endpoint (Day 29)
Reported as:
Median · Units on a scale
Clinical Global Impression of Improvement (CGI-I) Score at Endpoint of Double Blind Phase
Units on a scalePlacebo: 2 Times Per WeekKetamine: 2 Times Per WeekPlacebo: 3 Times Per WeekKetamine: 3 Times Per Week
Clinical Global Impression of Improvement (CGI-I) Score at Endpoint of Double Blind Phase4.0 ± 3.792.0 ± 4.914.0 ± 5.832.0 ± 5.28
SecondaryChange in Patient Global Impression-Severity (PGI-S) Score From Baseline to Endpoint (Day 29)

The PGI-S is an 11-point (0 to 10) scale that required the participant to rate the severity of their illness at the time of assessment, relative to the participants past experience. Considering their total experience, the participant was to assess the severity of their depression illness at the time of rating as none, mild, moderate or severe. The scale is rated as, 0=very well and 10=very poor.

Time frame:
Baseline (Day 1) and Endpoint (Day 29)
Reported as:
Median · Units on a scale
Change in Patient Global Impression-Severity (PGI-S) Score From Baseline to Endpoint (Day 29)
Units on a scalePlacebo: 2 Times Per WeekKetamine: 2 Times Per WeekPlacebo: 3 Times Per WeekKetamine: 3 Times Per Week
Baseline (n=15,18,16,17)8.0 ± 3.797.5 ± 4.918.0 ± 5.837.0 ± 5.28
Change at Endpoint (n=15,18,16,17)0.0 ± 10.61-4.0 ± 6.60-1.0 ± NA-3.0 ± 10.61
SecondaryPatient Global Impression-Change (PGI-C) Score at Endpoint of Double Blind Phase

The PGI-C is a 7-point scale that required the subject to assess how much their illness had improved or worsened relative to a baseline state at the beginning of the intervention. The response options were: very much improved; much improved; improved (just enough to make a difference); no change; worse (just enough to make a difference); much worse; or very much worse. The scale is rated as, 1=very much improved and 7=very much worse.

Time frame:
Endpoint (Day 29)
Reported as:
Median · Units on a scale
Patient Global Impression-Change (PGI-C) Score at Endpoint of Double Blind Phase
Units on a scalePlacebo: 2 Times Per WeekKetamine: 2 Times Per WeekPlacebo: 3 Times Per WeekKetamine: 3 Times Per Week
Patient Global Impression-Change (PGI-C) Score at Endpoint of Double Blind Phase4.0 ± 3.792.0 ± 4.914.0 ± 5.833.0 ± 5.28
SecondaryMaximum Observed Plasma Concentration (Cmax) of Ketamine

The Cmax is the maximum observed plasma concentration of drug.

Time frame:
Pre-infusion, 20, 40 (End of the Infusion), 45, 50, 60, 90, 120, 180, 240 and 360 minutes post-infusion on Day 1 and Day 15
Reported as:
Mean · nanogram per milliliter (ng/ml)
Maximum Observed Plasma Concentration (Cmax) of Ketamine
nanogram per milliliter (ng/ml)Ketamine: 2 Times Per WeekKetamine: 3 Times Per Week
Day 1 (n=16,16)207 ± 83.0168 ± 34.4
Day 15 (n=14,15)219 ± 69.4189 ± 74.4
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of Ketamine

The Tmax is defined as actual sampling time to reach maximum observed drug concentration.

Time frame:
Pre-infusion, 20, 40 (End of the Infusion), 45, 50, 60, 90, 120, 180, 240 and 360 minutes post-infusion on Day 1 and Day 15
Reported as:
Median · Hour
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Ketamine
HourKetamine: 2 Times Per WeekKetamine: 3 Times Per Week
Day 1 (n=16,16)0.67 ± 83.00.66 ± 34.4
Day 15 (n=14,15)0.67 ± 69.40.67 ± 74.4
SecondaryArea Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time (AUC[0-last])

The AUC(0-last) is the area under the plasma concentration-time curve from time zero to last quantifiable time.

Time frame:
Pre-infusion, 20, 40 (End of the Infusion), 45, 50, 60, 90, 120, 180, 240 and 360 minutes post-infusion on Day 1 and Day 15
Reported as:
Mean · hour*nanogram per milliliter
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time (AUC[0-last])
hour*nanogram per milliliterKetamine: 2 Times Per WeekKetamine: 3 Times Per Week
Day 1 (n=16,15)312 ± 67.9295 ± 42.8
Day 15 (n=14,14)342 ± 66.7293 ± 65.6
SecondaryArea Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity])

The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC (last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.

Time frame:
Pre-infusion, 20, 40 (End of the Infusion), 45, 50, 60, 90, 120, 180, 240 and 360 minutes post-infusion on Day 1 and Day 15
Reported as:
Mean · hour*nanogram per milliliter
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity])
hour*nanogram per milliliterKetamine: 2 Times Per WeekKetamine: 3 Times Per Week
Day 1 (n=13,13)369 ± 79.9344 ± 47.3
Day 15 (n=9,8)416 ± 68.9340 ± 94.0
SecondaryTotal Systemic Clearance (CL) of Ketamine

The CL is a quantitative measure of the rate at which a drug substance is removed from the body.

Time frame:
Pre-infusion, 20, 40 (End of the Infusion), 45, 50, 60, 90, 120, 180, 240 and 360 minutes post-infusion on Day 1 and Day 15
Reported as:
Mean · liter per hour
Total Systemic Clearance (CL) of Ketamine
liter per hourKetamine: 2 Times Per WeekKetamine: 3 Times Per Week
Day 1 (n=13,13)113 ± 35.1108 ± 21.4
Day 15 (n=9,8)93.9 ± 15.6117 ± 22.3
SecondaryVolume of Distribution at Steady-State (Vss) of Ketamine

The Vss is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of ketamine at steady state.

Time frame:
Pre-infusion, 20, 40 (End of the Infusion), 45, 50, 60, 90, 120, 180, 240 and 360 minutes post-infusion on Day 1 and Day 15
Reported as:
Mean · liter
Volume of Distribution at Steady-State (Vss) of Ketamine
literKetamine: 2 Times Per WeekKetamine: 3 Times Per Week
Day 1 (n=13,13)275 ± 114276 ± 77.2
Day 15 (n=9,8)239 ± 61.2290 ± 64.9
SecondaryElimination Half-Life (t1/2)

The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).

Time frame:
Pre-infusion, 20, 40 (End of the Infusion), 45, 50, 60, 90, 120, 180, 240 and 360 minutes post-infusion on Day 1 and Day 15
Reported as:
Mean · hour
Elimination Half-Life (t1/2)
hourKetamine: 2 Times Per WeekKetamine: 3 Times Per Week
Day 1 (n=13,13)2.18 ± 0.432.18 ± 0.40
Day 15 (n=9,8)2.39 ± 0.362.21 ± 0.36

Adverse events

Collected over Screening up to Follow up (3 Weeks After Last Dose of Study Drug Administration). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo: 2 Times Per Week—0/16 (0%)9/16 (56.3%)
Ketamine: 2 Times Per Week—2/18 (11.1%)15/18 (83.3%)
Placebo: 3 Times Per Week—0/16 (0%)8/16 (50%)
Ketamine: 3 Times Per Week—0/17 (0%)13/17 (76.5%)
Most frequent serious events
Most frequent serious events
EventPlacebo: 2 Times Per WeekKetamine: 2 Times Per WeekPlacebo: 3 Times Per WeekKetamine: 3 Times Per Week
AnxietyPsychiatric disorders0/161/180/160/17
Suicide AttemptPsychiatric disorders0/161/180/160/17
Most frequent other events
Showing 10 of 76
Most frequent other events
EventPlacebo: 2 Times Per WeekKetamine: 2 Times Per WeekPlacebo: 3 Times Per WeekKetamine: 3 Times Per Week
HeadacheNervous system disorders5/164/181/167/17
DissociationPsychiatric disorders0/165/180/161/17
NauseaGastrointestinal disorders1/163/182/164/17
DizzinessNervous system disorders1/164/180/162/17
AnxietyPsychiatric disorders0/164/180/161/17
HypoaesthesiaNervous system disorders0/162/180/163/17
FatigueGeneral disorders0/160/180/162/17
ParaesthesiaNervous system disorders0/161/180/162/17
Vision BlurredEye disorders0/162/180/160/17
Blood Pressure IncreasedInvestigations0/162/180/160/17

Baseline characteristics

The Intent-To-Treat (ITT) analysis set is defined as participants who were randomized and received at least 1 dose of the study drug.

Age, Continuous
Age, Continuous(years)Placebo: 2 Times Per WeekKetamine: 2 Times Per WeekPlacebo: 3 Times Per WeekKetamine: 3 Times Per WeekTotal
Mean40.3 ± 11.7945.7 ± 9.5846.1 ± 10.5143.3 ± 11.9943.9 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)Placebo: 2 Times Per WeekKetamine: 2 Times Per WeekPlacebo: 3 Times Per WeekKetamine: 3 Times Per WeekTotal
Female121291245
Male467522
Region of Enrollment
Region of Enrollment(participants)Placebo: 2 Times Per WeekKetamine: 2 Times Per WeekPlacebo: 3 Times Per WeekKetamine: 3 Times Per WeekTotal
USA1618161767
08

Study locations

13 sites
  • Birmingham, Alabama, United States
  • Little Rock, Arkansas, United States
  • Centennial, Colorado, United States
  • Hartford, Connecticut, United States
  • New Haven, Connecticut, United States
  • Atlanta, Georgia, United States
  • Rockville, Maryland, United States
  • Marlton, New Jersey, United States
  • New York, New York, United States
  • Allentown, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Dallas, Texas, United States
  • Salt Lake City, Utah, United States
09

References and documents

Publications

  • Lewis S, Romano C, De Bruecker G, Murrough JW, Shelton R, Singh JB, Jamieson C. Analysis of Clinical Trial Exit Interview Data in Patients with Treatment-Resistant Depression. Patient. 2019 Oct;12(5):527-537. doi: 10.1007/s40271-019-00369-8. PubMed 31270774 ↗
  • Johnson KM, Devine JM, Ho KF, Howard KA, Saretsky TL, Jamieson CA. Evidence to Support Montgomery-Asberg Depression Rating Scale Administration Every 24 Hours to Assess Rapid Onset of Treatment Response. J Clin Psychiatry. 2016 Dec;77(12):1681-1686. doi: 10.4088/JCP.15m10253. PubMed 28086004 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2012 to primary completion in Sep 2013, 13 months.

Results were first posted in Aug 2016, 2 years 10 months after primary completion. A results delay was requested in Jun 2014.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 13 months is below that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2012
First posted
Jun 26, 2012
StartActual
Aug 6, 2012
Primary completionActual
Sep 12, 2013
CompletionActual
Sep 12, 2013
Results delay requested
Jun 25, 2014
Results first posted
Aug 5, 2016
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01627782
Responsible party
Sponsor
First posted
Jun 26, 2012
Start date
Aug 6, 2012
Primary completion
Sep 12, 2013
Completion
Sep 12, 2013
Results posted
Aug 5, 2016
Last update
Apr 29, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketamine

Start the discussion